Skip to content

CHIZAP: Community- and Health Facility-Based Intervention With Zinc as Adjuvant Therapy for Childhood Pneumonia

Community- and Health Facility-based Intervention With Zinc as Adjuvant Therapy for Pneumonia to Enhance Child Health and Nutrition

Status
Completed
Phases
Phase 2Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00148733
Enrollment
2628
Registered
2005-09-08
Start date
2004-01-31
Completion date
2008-01-31
Last updated
2022-03-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pneumonia

Keywords

Child, pneumonia, Zinc, clinical trial, Nepal, nutrition, therapeutic

Brief summary

The aim of the study described is to measure the degree with which zinc given as adjunct therapy to standard antibiotic treatment during childhood pneumonia reduces the risk of treatment failure and the duration of the illness.

Detailed description

Hypothesis: Zinc deficiency is a major public health problem in developing counties. Poor zinc status is associated with stunted growth and reduced resistance to infections. Several in vitro experiments and in vivo studies in animals and humans have demonstrated detrimental effects of zinc depletion on almost all facets of the immune system. The epithelial linings in the gut and in the respiratory tract are important for the resistance to infections and continuous cell division is required for proper function of these barriers. Zinc is crucial for cellular division and for the maintenance of organs with cells with a rapid turnover, including epithelial cells. Clinical trials in children in developing countries have demonstrated improved growth and reduced prevalence of diarrhea and respiratory tract infections following zinc supplementation. Furthermore, zinc has a well-documented therapeutic effect when given during acute or persistent diarrhea. The effect of zinc may be explained by correction of a deficiency state and/or by a pharmacological, as yet poorly described, action. Due to the promising results from previous studies, WHO are now supporting large clinical trials in Nepal, India and Tanzania to assess whether routine zinc supplementation reduces mortality in early childhood. If the results of these trials show a mortality reduction, routine zinc supplementation or zinc dense foods may be promoted. However, while the first approach is logistically difficult and expensive, the second approach is difficult because zinc dense foods and foods with low phytic acid content are expensive and not readily available. Moreover, both approaches may be perceived to be incompatible with the current breast-feeding recommendations for the youngest children in most developing countries. There is limited information on zinc as adjunct therapy for pneumonia. A recent hospital-based study in young children with severe pneumonia, showed that the zinc group had a faster recovery, resulting in a shortening of stay in hospital of one day. However, this study was small and no community based study has been conducted so far. Whether zinc has an effect during respiratory infections has to be assessed in studies with larger sample sizes in children with less severe disease and should be repeated in children with more severe disease. Short-term zinc administration during infections may become an alternative or an addition to long-term supplementation or promotion of zinc dense foods. Furthermore, therapeutic administration of zinc will not interfere with the current breast-feeding recommendations. Hypothesis: Zinc as adjunct therapy for pneumonia may lead to faster recovery. Furthermore, long-term beneficial effects may include improved immuno-nutritional status measured by thymus size, less morbidity and improved growth. Comparison: Duration of illness, risk of treatment failure, for those with severe pneumonia: length of hospital stay. Number of non-injury clinic visits and hospitalizations during the intervention with Zinc and an in a 6 month period after enrolment. Growth assessed by anthropometry and thymus size assessed by ultrasonography. Explore the efficacy of zinc in etiology-sub groups including those defined by nutritional status, inflammation, fever, gender, breastfeeding status and viral etiology.

Interventions

DRUGZinc

Dissolvable zinc tablet 10 mg elemental zinc per day for infants 20 mg elemental zinc per day for children 12 to 35 months

Sponsors

Tribhuvan University, Nepal
CollaboratorOTHER
Statens Serum Institut
CollaboratorOTHER
All India Institute of Medical Sciences
CollaboratorOTHER
IRD, Epidemiologie et Prevention, Montpelier, France
CollaboratorUNKNOWN
Society for Applied Studies
CollaboratorOTHER
Centre For International Health
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
2 Months to 3 Years
Healthy volunteers
No

Inclusion criteria

* Pneumonia: Child presenting with cough or difficult breathing and elevated respiratory rate. * Severe pneumonia: Child presenting with cough or difficult breathing and chest indrawing , but without any of the following danger signs: * not able to drink/breastfeed, * vomit everything, * has had convulsions, * is lethargic or unconscious. * Must be able to take Zinc

Exclusion criteria

* The child requires special care for severe illness other than pneumonia * Severe malnutrition defined as being \< 70% National Center for Health Statistics (NCHS) median weight for height * Presence of congenital heart disease * Documented tuberculosis * Any antibiotic treatment during the last 48 hours * The child was enrolled less than 6 months ago * Presence of dysentery * Cough for more than 14 days

Design outcomes

Primary

MeasureTime frameDescription
Adverse Effects14 daysVomiting, regurgitation, pain in abdomen for 15 minutes after zinc or placebo administration.
Risk of Treatment Failure.Within 2 weeks after enrollmentEnrolled children will be followed and given zinc or placebo for 14 days. We will compare the proportion with treatment failure (i.e. lack of improvement within 3 days) between the two groups
Non-injury Clinic Visits and Hospital Admissions After Treatment Has Been InitiatedWithin 2 weeks after enrollmentWe will measure to what extent the intervention can reduce the number of severe events.
Active and Passive Morbidity Surveillance for Six Months After the 14-day Supplementation Period is Completedsix monthsWe will measure to what extent short term zinc administration has an impact on growth and morbidity for up to 6 months after end of supplementation
Difference in Growth and Thymic Size Between the Treatment Groups Measured at Three and Six Months After the Zinc Supplementationsix monthsThymus size will be measured using ultrasonography and compared between the two groups. at two occasions 2.5 and 6 months after end of supplementation

Secondary

MeasureTime frameDescription
Effect Modifiers for the Effect of Zinc Given During PneumoniaWithin 2 weeks after enrollmentWe will also measure of there are factors at baseline that modifies the effect of zinc. Whether the following are modifiers for the above-mentioned effect of zinc given during pneumonia: i.severe inflammation, reflected in: high fever and/or elevated plasma C-reactive protein (CRP) concentration
The Efficacy of Zinc According to Breast Feeding Status and in Different Age CategoriesWithin 2 weeks after enrollmentWe will measure to what extent breastfeeding status modifies the effect of zinc on pneumonia
The Efficacy of Zinc in Malnourished and Non-malnourished ChildrenWithin 2 weeks after enrollmentWe will compare the efficacy of zinc in those that are stunted, wasted or underweight with those who are not.
Will Presence of a RNA Virus Modify the Effect of Zinc14 daysWe will compare the efficacy of zinc according to virus detected in nasopharyngeal secretions
Folate, Cobalamin and Vitamin D Status of the Enrolled Children14 daysAnd whether or not these vitamins predict treatment failure and duration of illness.

Countries

Nepal

Participant flow

Participants by arm

ArmCount
Zinc
Zinc sulphate 10 or 20 mg (elemental zinc) per day. Intervention and placebo given perorally mixed with approximately 5 mL of breastmilk or clean water Zinc: Dissolvable zinc tablet 10 mg elemental zinc per day for infants 20 mg elemental zinc per day for children 12 to 35 months
1,314
Placebo
Placebo Zinc: Dissolvable zinc tablet 10 mg elemental zinc per day for infants 20 mg elemental zinc per day for children 12 to 35 months
1,314
Total2,628

Baseline characteristics

CharacteristicZincPlaceboTotal
Age, Continuous7.3 months
STANDARD_DEVIATION 7.4
7.2 months
STANDARD_DEVIATION 7.2
7.2 months
STANDARD_DEVIATION 7.3
Sex: Female, Male
Female
575 Participants576 Participants1151 Participants
Sex: Female, Male
Male
739 Participants738 Participants1477 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
181 / 1,31453 / 1,314
serious
Total, serious adverse events
0 / 1,3140 / 1,314

Outcome results

Primary

Active and Passive Morbidity Surveillance for Six Months After the 14-day Supplementation Period is Completed

We will measure to what extent short term zinc administration has an impact on growth and morbidity for up to 6 months after end of supplementation

Time frame: six months

Primary

Adverse Effects

Vomiting, regurgitation, pain in abdomen for 15 minutes after zinc or placebo administration.

Time frame: 14 days

Primary

Difference in Growth and Thymic Size Between the Treatment Groups Measured at Three and Six Months After the Zinc Supplementation

Thymus size will be measured using ultrasonography and compared between the two groups. at two occasions 2.5 and 6 months after end of supplementation

Time frame: six months

Primary

Non-injury Clinic Visits and Hospital Admissions After Treatment Has Been Initiated

We will measure to what extent the intervention can reduce the number of severe events.

Time frame: Within 2 weeks after enrollment

Primary

Risk of Treatment Failure.

Enrolled children will be followed and given zinc or placebo for 14 days. We will compare the proportion with treatment failure (i.e. lack of improvement within 3 days) between the two groups

Time frame: Within 2 weeks after enrollment

ArmMeasureValue (NUMBER)
ZincRisk of Treatment Failure.267 participants
PlaceboRisk of Treatment Failure.253 participants
Secondary

Effect Modifiers for the Effect of Zinc Given During Pneumonia

We will also measure of there are factors at baseline that modifies the effect of zinc. Whether the following are modifiers for the above-mentioned effect of zinc given during pneumonia: i.severe inflammation, reflected in: high fever and/or elevated plasma C-reactive protein (CRP) concentration

Time frame: Within 2 weeks after enrollment

Secondary

Folate, Cobalamin and Vitamin D Status of the Enrolled Children

And whether or not these vitamins predict treatment failure and duration of illness.

Time frame: 14 days

Secondary

The Efficacy of Zinc According to Breast Feeding Status and in Different Age Categories

We will measure to what extent breastfeeding status modifies the effect of zinc on pneumonia

Time frame: Within 2 weeks after enrollment

Secondary

The Efficacy of Zinc in Malnourished and Non-malnourished Children

We will compare the efficacy of zinc in those that are stunted, wasted or underweight with those who are not.

Time frame: Within 2 weeks after enrollment

Secondary

Will Presence of a RNA Virus Modify the Effect of Zinc

We will compare the efficacy of zinc according to virus detected in nasopharyngeal secretions

Time frame: 14 days

Source: ClinicalTrials.gov · Data processed: Mar 31, 2026